SPAS(SH:603168)2025-01-17 09:05Financial Performance Forecast - The company expects a net profit attributable to shareholders of the parent company for 2024 to be between -148.8 million and -99.2 million CNY[4] - The expected net profit attributable to shareholders of the parent company, excluding non-recurring gains and losses, is projected to be between -129.6 million and -86.4 million CNY for 2024[4] - In the same period last year, the net profit attributable to shareholders was 25.41 million CNY, while the net profit excluding non-recurring gains and losses was -4.01 million CNY[5] - The earnings per share for the previous year was 0.07 CNY[5] Reasons for Expected Loss - The main reasons for the expected loss include a decrease in sales volume of key products like eye drops and cephalosporins due to macroeconomic and market supply-demand changes[7] - The company has increased its goodwill impairment provision compared to the same period last year, and investment income has decreased[7] Performance Forecast Reliability - The performance forecast data is preliminary and has not been audited by a registered accountant[8] - There are currently no significant uncertainties affecting the accuracy of the performance forecast[8] - Investors are advised to pay attention to investment risks as the forecast data is subject to change pending the official 2024 annual report[9]